Stem cell transplantation for mantle cell lymphoma: Not yet the standard of care

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

In summary, Engman and coworkers describe a rare case of syngeneic SCT in mantle cell lymphoma, which serves as an intriguing model to explore the benefit of high-dose strategies in this disease. Although these therapies have gained widespread use, their applicability is limited to a relatively small proportion of patients with MCL, and their effect on outcome is unclear. Continued prospective studies of these approaches are needed. The identification of new rational therapeutic targets in MCL has resulted in the recent introduction of many new agents including proteasome and mammalian target of rapamycin inhibitors.12,13 Early clinical trials of these agents have been promising and some are now being assessed as components of first-line therapy in this disease. If results in early phase studies are confirmed, the use of dose-intensive therapy may be more limited in patients with MCL in the future.

Original languageEnglish (US)
Pages (from-to)323-324
Number of pages2
JournalClinical Advances in Hematology and Oncology
Volume7
Issue number5
StatePublished - Jun 9 2009
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Stem Cell Transplantation
Standard of Care
Proteasome Endopeptidase Complex
Sirolimus
Therapeutics
Clinical Trials
Prospective Studies

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Stem cell transplantation for mantle cell lymphoma : Not yet the standard of care. / Sweetenham, John W.

In: Clinical Advances in Hematology and Oncology, Vol. 7, No. 5, 09.06.2009, p. 323-324.

Research output: Contribution to journalReview article

@article{99f4714367734cbd9d4f0c8aed935b60,
title = "Stem cell transplantation for mantle cell lymphoma: Not yet the standard of care",
abstract = "In summary, Engman and coworkers describe a rare case of syngeneic SCT in mantle cell lymphoma, which serves as an intriguing model to explore the benefit of high-dose strategies in this disease. Although these therapies have gained widespread use, their applicability is limited to a relatively small proportion of patients with MCL, and their effect on outcome is unclear. Continued prospective studies of these approaches are needed. The identification of new rational therapeutic targets in MCL has resulted in the recent introduction of many new agents including proteasome and mammalian target of rapamycin inhibitors.12,13 Early clinical trials of these agents have been promising and some are now being assessed as components of first-line therapy in this disease. If results in early phase studies are confirmed, the use of dose-intensive therapy may be more limited in patients with MCL in the future.",
author = "Sweetenham, {John W.}",
year = "2009",
month = "6",
day = "9",
language = "English (US)",
volume = "7",
pages = "323--324",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "5",

}

TY - JOUR

T1 - Stem cell transplantation for mantle cell lymphoma

T2 - Not yet the standard of care

AU - Sweetenham, John W.

PY - 2009/6/9

Y1 - 2009/6/9

N2 - In summary, Engman and coworkers describe a rare case of syngeneic SCT in mantle cell lymphoma, which serves as an intriguing model to explore the benefit of high-dose strategies in this disease. Although these therapies have gained widespread use, their applicability is limited to a relatively small proportion of patients with MCL, and their effect on outcome is unclear. Continued prospective studies of these approaches are needed. The identification of new rational therapeutic targets in MCL has resulted in the recent introduction of many new agents including proteasome and mammalian target of rapamycin inhibitors.12,13 Early clinical trials of these agents have been promising and some are now being assessed as components of first-line therapy in this disease. If results in early phase studies are confirmed, the use of dose-intensive therapy may be more limited in patients with MCL in the future.

AB - In summary, Engman and coworkers describe a rare case of syngeneic SCT in mantle cell lymphoma, which serves as an intriguing model to explore the benefit of high-dose strategies in this disease. Although these therapies have gained widespread use, their applicability is limited to a relatively small proportion of patients with MCL, and their effect on outcome is unclear. Continued prospective studies of these approaches are needed. The identification of new rational therapeutic targets in MCL has resulted in the recent introduction of many new agents including proteasome and mammalian target of rapamycin inhibitors.12,13 Early clinical trials of these agents have been promising and some are now being assessed as components of first-line therapy in this disease. If results in early phase studies are confirmed, the use of dose-intensive therapy may be more limited in patients with MCL in the future.

UR - http://www.scopus.com/inward/record.url?scp=66349100581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349100581&partnerID=8YFLogxK

M3 - Review article

C2 - 19521321

AN - SCOPUS:66349100581

VL - 7

SP - 323

EP - 324

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 5

ER -